« FDA Approvals - Kensey Nash Receives FDA 510(k) Clearance For TriActiv FX(R) Embolic | Main | FDA Approvals - St. Jude Medical Announces FDA Approval of Atlas II ICD »

Gardasil Cervical Cancer Vaccine (Gardisil)

GARDASIL (R), Merck's Investigational Cervical Cancer Vaccine, to Receive Priority Review from the U.S. Food and Drug (FinanzNachrichten)
Merck&Co., Inc. (Gardisil) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for GARDASIL(R) (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine) and that the investigational cervical cancer vaccine will be given priority review by the agency.

 

©2006 FDA-News.com. All rights reserved.